Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27109074 | 0.82 | HRH3 (0.42) | GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL31680947 | 0.79 | GNAO1 (0.38) | GNAO1GNAI3GNAI1 | |
| SCHEMBL27097459 | 0.79 | GNAO1 (0.42) | GNAO1GNAI3GNAI1MAOAMAOB | |
| SCHEMBL27097566 | 0.79 | GNAO1 (0.42) | GNAO1GNAI3GNAI1MAOAMAOB | |
| SCHEMBL31722644 | 0.79 | HRH2 (0.41) | GNAO1GNAI3GNAI1CYP2D6CYP2C9 | |
| SCHEMBL27097440 | 0.77 | GNAO1 (0.56) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL12064339 | 0.76 | GNAO1 (0.48) | GNAO1GNAI3GNAI1MAOAMAOB | |
| SCHEMBL23133951 | 0.76 | CHRM3 (0.42) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL4240682 | 0.76 | CHRM3 (0.44) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL31722729 | 0.75 | SIGMAR1 (0.37) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | GNAO1 829/4885GNAI3 1058/4885GNAI1 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.